CADL
Income statement / Annual
Last year (2024), Candel Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Candel Therapeutics, Inc.'s net income was -$55.18 M.
See Candel Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$125,000.00 |
$125,000.00 |
$125,000.00 |
$125,000.00 |
| Cost of Revenue |
$0.00
|
$23.98 M
|
$987,000.00
|
$232,000.00
|
$0.00
|
$6.61 M
|
| Gross Profit |
$0.00
|
-$23.98 M
|
-$862,000.00
|
-$107,000.00
|
$125,000.00
|
-$6.48 M
|
| Gross Profit Ratio |
0
|
0
|
-6.9
|
-0.86
|
1
|
-51.86
|
| Research and Development Expenses |
$18.32 M
|
$24.51 M
|
$20.79 M
|
$15.18 M
|
$8.75 M
|
$6.61 M
|
| General & Administrative Expenses |
$14.06 M
|
$13.72 M
|
$14.06 M
|
$10.67 M
|
$5.18 M
|
$2.56 M
|
| Selling & Marketing Expenses |
$0.00
|
$687,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.06 M
|
$14.41 M
|
$14.06 M
|
$10.67 M
|
$5.18 M
|
$2.56 M
|
| Other Expenses |
$0.00
|
-$24.51 M
|
-$48,000.00
|
-$1.08 M
|
-$624,000.00
|
-$571,000.00
|
| Operating Expenses |
$33.37 M
|
$14.41 M
|
$34.80 M
|
$24.78 M
|
$13.31 M
|
$8.59 M
|
| Cost And Expenses |
$0.00
|
$38.39 M
|
$34.80 M
|
$24.78 M
|
$13.31 M
|
$8.59 M
|
| Interest Income |
$1.09 M
|
$0.00
|
$490,000.00
|
$53,000.00
|
$111,000.00
|
$1.07 M
|
| Interest Expense |
-$2.09 M
|
$514,000.00
|
$490,000.00
|
$53,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$990,000.00
|
$960,000.00
|
$987,000.00
|
$232,000.00
|
$91,000.00
|
$43,000.00
|
| EBITDA |
-$52.10 M |
-$37.43 M |
-$17.32 M |
-$25.49 M |
-$13.72 M |
-$8.20 M |
| EBITDA Ratio |
0
|
0
|
-138.54
|
-203.95
|
-109.75
|
-65.58
|
| Operating Income Ratio |
0
|
0
|
-277.78
|
-205.81
|
-110.48
|
-72.3
|
| Total Other Income/Expenses Net |
-$21.81 M
|
$452,000.00
|
$15.93 M
|
-$10.40 M
|
-$3.87 M
|
$797,000.00
|
| Income Before Tax |
-$55.18 M
|
-$37.94 M
|
-$18.79 M
|
-$36.12 M
|
-$17.68 M
|
-$8.24 M
|
| Income Before Tax Ratio |
0
|
0
|
-150.35
|
-288.99
|
-141.44
|
-65.92
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$15.93 M
|
$53,000.00
|
$4.49 M
|
-$226,000.00
|
| Net Income |
-$55.18 M
|
-$37.94 M
|
-$2.87 M
|
-$36.18 M
|
-$22.17 M
|
-$8.01 M
|
| Net Income Ratio |
0
|
0
|
-22.93
|
-289.42
|
-177.39
|
-64.11
|
| EPS |
-1.74 |
-1.31 |
-0.0994 |
-1.26 |
-0.76 |
-0.27 |
| EPS Diluted |
-1.74 |
-1.31 |
-0.0994 |
-1.26 |
-0.76 |
-0.27 |
| Weighted Average Shares Out |
$31.68 M
|
$28.94 M
|
$28.82 M
|
$28.69 M
|
$29.15 M
|
$29.15 M
|
| Weighted Average Shares Out Diluted |
$31.68 M
|
$28.94 M
|
$28.82 M
|
$28.69 M
|
$29.15 M
|
$29.15 M
|
| Link |
|
|
|
|
|
|
